(Total Views: 282)
Posted On: 03/22/2019 1:11:27 PM
Post# of 99138
$QBIO Q BioMed’s Diagnostic Kit Designed to Serve Unmet Need for 70 Million Glaucoma Sufferers
Q BioMed Inc. (OTC – QBIO - $2.052 - NR) and its key technology partners are set to initiate development of an industry-changing diagnostic kit for monitoring glaucoma severity and progression. Pending FDA clearance, which could come sooner than many biotech investors might expect, this kit offers the potential to improve the quality of life for glaucoma sufferers by helping preserve visual function in glaucoma patients through accurate monitoring of disease progression. As a result, this diagnostic offers substantial future value to the Company.
Diagnostic Kit Offers Critical, First-of-its-Kind Functionality
https://www.goldmanresearch.com/201903201237/...arket.html
Q BioMed Inc. (OTC – QBIO - $2.052 - NR) and its key technology partners are set to initiate development of an industry-changing diagnostic kit for monitoring glaucoma severity and progression. Pending FDA clearance, which could come sooner than many biotech investors might expect, this kit offers the potential to improve the quality of life for glaucoma sufferers by helping preserve visual function in glaucoma patients through accurate monitoring of disease progression. As a result, this diagnostic offers substantial future value to the Company.
Diagnostic Kit Offers Critical, First-of-its-Kind Functionality
https://www.goldmanresearch.com/201903201237/...arket.html
(0)
(0)
